Acquisition of Debiopharm's investment portfolio company Kaiku Health broadens patient access to digital oncology intervention

[Ort] (ots) -

- Debiopharm announces successful exit deal for Kaiku Health, a
Finnish start-up specializing in digital solutions for improved
patient outcomes and experience
- Kaiku's acquisition by the Swedish company Elekta allows
thousands of cancer treatment centers to gain access to the
start-up's novel digital patient monitoring platform

Debiopharm ( http://www.debiopharm.com ), a Swiss biopharmaceutical company,
announced today the successful exit and acquisition of their investment
portfolio company Kaiku Health, a Helsinki-based digital therapeutics company
specializing in improving the quality of life of cancer patients. The
acquisition made by the publicly traded, Stockholm-based company Elekta
(EKTA-B.ST), one of the global market leaders in precision radiation medicine,
enables a reach to over 4000 oncology centers managing thousands of cancer
patients worldwide with Elekta's software suite, extending the company's digital
health offering.

In 2018, Debiopharm became the Series A lead investor in Kaiku Health in order
to support the active adoption of their technology by hospitals, clinics, and
pharmaceutical companies. The investment decision aligned with Debiopharm's
vision is to invest in start-ups that change the way that patients are treated
and the way that drugs are developed. The corporate fund specializes in
disruptive digital health investments while actively helping the companies bring
their technologies to a clinical reality.

It's really thrilling to see our start-up investment companies grow and move to
the next step of reaching more of the patients who can benefit from their
innovation" explained Tanja Dowe, CEO of Debiopharm Innovation Fund SA and
former Chairwoman of Kaiku Health . "The growing patient base through Elekta
will strengthen Kaiku Health's capabilities to develop patient-centric and
outcome-driven solutions for cancer patients, in some cases in collaboration
with pharmaceutical companies. In the era of precision medicine, these outcomes
play an important role for the development of pharmaceutical therapies."

Debiopharm remains an active investor in digital health start-ups around the
world. As the chairwoman of the board, Debiopharm Innovation Fund SA CEO, Tanja
Dowe provided strategic and practical guidance to sustain and grow the
start-up's network, pharmaceutical know-how and international impact.

Kaiku Health has been particularly implicated in immunooncology, where faster
detection of predictive symptoms can lead to improved toxicity management. The
platform offers cancer patients the ability to stay better connected to their